Back to Results

XORTX Therapeutics Inc (XRTX)

XORTX Therapeutics Inc (NASDAQ:XRTX) is a Healthcare-sector Pharmaceuticals company whose common stock is listed on NASDAQ. The XRTX security is a common equity instrument in the common equity context, so it represents ownership in the company rather than a fund, bond, or derivative product. Based on available company information, XORTX focuses on pharmaceutical research and development for conditions associated with uric acid and kidney-related disorders. Its activity appears centered on drug development rather than broad commercial operations. Investors looking at this security are therefore assessing a clinical-stage pharmaceutical issuer with exposure to healthcare and biotechnology-related development risks.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-XRTX
$2.92
52.1% Upside
Bargain
$69.05 3,496.3% Upside
Not available
Bargain
Fair
0.0%
0.6x
3.433 M
2.069 M
0.0%
98.6%
-12.6
136.4%
Valuation • Fair Value

XORTX Therapeutics Inc (NASDAQ-XRTX) Fair Value by Valuation Model

Review the available estimates for XORTX Therapeutics Inc (NASDAQ-XRTX), including Comps Fair Value.

Primary Valuation Read

Fair Value

$2.92

Estimated upside of 52.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$2.92

Comparable-company valuation reference.

Analyst Price Target

$69.05 3,496.3% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use the 4 available valuation references for XORTX Therapeutics Inc (NASDAQ-XRTX) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for XORTX Therapeutics Inc (NASDAQ-XRTX)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

3.235 M

Forward revenue estimate.

EBITDA

-2.146 M

Current operating profitability reference.

EBITDA Forecast

76.525 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review XORTX Therapeutics Inc (NASDAQ-XRTX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for XORTX Therapeutics Inc (NASDAQ-XRTX)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Altman Z-Score

-12.6

Lower score that deserves closer risk review.

FCF / Net Income

136.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for XORTX Therapeutics Inc (NASDAQ-XRTX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for XORTX Therapeutics Inc (NASDAQ-XRTX)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for XORTX Therapeutics Inc (NASDAQ-XRTX). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

XORTX Therapeutics Inc (NASDAQ-XRTX) Stock Forecast & Technical Outlook

Review XORTX Therapeutics Inc (NASDAQ-XRTX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for XORTX Therapeutics Inc (NASDAQ-XRTX) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for XORTX Therapeutics Inc (NASDAQ-XRTX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for XORTX Therapeutics Inc (NASDAQ-XRTX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for XORTX Therapeutics Inc (NASDAQ-XRTX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for XORTX Therapeutics Inc (NASDAQ-XRTX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for XORTX Therapeutics Inc (NASDAQ-XRTX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, XORTX Therapeutics Inc (NASDAQ-XRTX) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

XORTX Therapeutics Inc (NASDAQ-XRTX) Stock FAQ

Data-supported answers about XORTX Therapeutics Inc (NASDAQ-XRTX), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$2.92
Estimated upside 52.1%
Valuation Rating
Undervalued
Estimated upside of 52.1%
Analyst Target
$69.05 3,496.3% Upside
Data is currently unavailable
Financial Health
Fair
Current financial-health read

The current fair value estimate for XORTX Therapeutics Inc (NASDAQ-XRTX) is $2.92. This implies an estimated upside of 52.1% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 52.1% versus the current market price.

The available analyst price target for XORTX Therapeutics Inc (NASDAQ-XRTX) is $69.05 3,496.3% Upside.

The current financial health read for XORTX Therapeutics Inc (NASDAQ-XRTX) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for XORTX Therapeutics Inc (NASDAQ-XRTX).

The current market capitalization listed for XORTX Therapeutics Inc is 3.433 M.

The current enterprise value listed for XORTX Therapeutics Inc is 2.069 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for XORTX Therapeutics Inc is NASDAQ-XRTX, and the stock is listed on NASDAQ.

XORTX Therapeutics Inc (NASDAQ-XRTX) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for XORTX Therapeutics Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for XORTX Therapeutics Inc is 98.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,027.7 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 650.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 266.2 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 191.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 157.7 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 128.8 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 101.9 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 100.8 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.801 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.423 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.198 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.653 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 29.504 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.446 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.628 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 11.943 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.202 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.884 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.161 B